The aim of this review is to assess the efficacy and safety of the TNF-alpha inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab and onercept) in patients with PsA when compared with placebo or current standard treatment.
This review will address four core questions.
1. What is the clinical efficacy of TNF-alpha inhibitors for the treatment of PsA in terms of:
- relieving symptoms?
- improving health related quality of life?
- delaying disease progression?
2. What are the risks (frequency and severity of adverse events) associated with use of TNF-alpha inhibitors in these patients?
This is a protocol.